Connor, Clark & Lunn Investment Management Ltd. Uni Qure N.V. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$4.82 - $6.93 $115,530 - $166,105	23,969 Added 143.67%	40,652 $211,000
Q4 2023 Feb 09, 2024	BUY	$5.63 - $8.27 $93,925 - $137,968	16,683 New	16,683 $112,000
Q2 2022 Aug 05, 2022	BUY	$13.15 - $20.45 $496,688 - $772,416	37,771 Added 25.37%	186,669 $3.48 Million
Q1 2022 May 12, 2022	SELL	$14.54 - $21.5 $527,831 - $780,493	-36,302 Reduced 19.6%	148,898 $2.69 Million
Q4 2021 Feb 10, 2022	BUY	$20.24 - $36.01 $158,317 - $281,670	7,822 Added 4.41%	185,200 $3.84 Million
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $4.61 Million - $6.78 Million	177,378 New	177,378 $5.68 Million
Q1 2021 May 13, 2021	SELL	$29.24 - $42.03 $217,925 - $313,249	-7,453 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $263,463 - $377,643	7,453 New	7,453 $269,000

Others Institutions Holding QURE

# of Institutions

142

Shares Held

35.3M

Call Options Held

1.54M

Put Options Held

389K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account